Connective tissue naevus (collagenoma) in a patient with benign joint hypermobility syndrome (Ehlers-Danlos syndrome type III) [3]

Clinical and Experimental Dermatology

Volumn 28, Issue 3, 2003, Pages 323-325

  Sidwell, R U ^a   Francis, N ^a   Grahame, R ^b   Pope, F M ^c   Bunker, C B ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; DESOGESTREL PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

ADULT; AUTOSOMAL DOMINANT DISORDER; CASE REPORT; CLINICAL FEATURE; COLLAGEN SYNTHESIS; COLLAGENOMA; CONNECTIVE TISSUE; CONNECTIVE TISSUE NEVUS; EHLERS DANLOS SYNDROME; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN TISSUE; LETTER; NEVUS; PRIORITY JOURNAL;

ADULT; COLLAGEN; COLLAGEN DISEASES; EHLERS-DANLOS SYNDROME; FEMALE; HAMARTOMA; HUMANS;

EID: 0038454789     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.2003.01236.x     Document Type: Letter

References (16)

1. Beighton PH, Solomon L, Soskolne CL. Articular mobility in an African population. Ann Rheum Dis 1973; 32: 413-7.
2. Grahame R. Joint hypermobility and genetic collagen disorders: are they related? Arch Dis Childhood 1999: 80: 188-91.
3. Beighton PH, de Paepe A, Danks D et al. International Nosology of Heritable Disorders of Connective Tissue, Berlin 1986. Am J Hum Genet 1988; 29: 581-94.
4. Grahame R, Bird HA, Child A et al. The Revised (Brighton 1998) Criteria for the Diagnosis of the Benign Joint Hypermobility Syndrome. J Rheumatol 2000; 27: 1777-9.
5. Beighton P, De Paepe A, Steinmann B et al. Ehlers-Danlos syndrome: revised nosology. Villefranches, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). Am J Med Genet 1998; 77: 31-7.
6. Narcisi P, Richards AJ, Ferguson SD, Pope FM. A family with Ehlers-Danlos syndrome type III/articular hypermobility syndrome has a glycine 637 to serine substitution in type III collagen. Hum Mol Genet 1994; 3: 1617-20.
7. Uitto J, Santa-Cruz DJ, Eisen AZ. Familial cutaneous collagenoma: genetic studies on a family. Br J Dermatol 1979; 101: 185-95.
8. Phillips P, Essa AS, Chetty R. Familial cutaneous collagenoma. J Am Acad Dermatol 1999; 40: 255-7.
9. Child AH. Joint hypermobility syndrome: inherited disorder of collagen synthesis. J Rheumatol 1986; 13: 239-43.
10. Boukhris R. Sex hormones and the skin. J Gynecol Obstet Biol Reprod (Paris) 1989; 18: 831-42.
11. Brincat MP. Hormone replacement therapy and the skin. Maturitas 2000; 35: 107-17.
12. Phillips TJ, Demircay Z, Sahu M. Hormonal effects on skin aging. Clin Geriatr Med 2001; 17: 661-72.
13. Sator PG, Schmidt JB, Sator MO et al. The influence of hormone replacement therapy on skin aging: a pilot study. Maturitas 2001; 39: 43-55.
14. Schmidt JB, Binder M, Demschik G et al. Treatment of skin aging with topical estrogens. Int J Dermatol 1996; 35: 669-74.
15. Khastgir G, Studd J, Holland N et al. Anabolic effect of long-term estrogen replacement on bone collagen in elderly postmenopausal women with osteoporosis. Osteoporos Int 2001; 12: 465-70.
16. Charlton WP, Coslett-Charlton LM, Ciccotti MG. Correlation of estradiol in pregnancy and anterior cruciate ligament laxity. Clin Orthop 2001; 387: 165-70.